Charles Schwab Investment Management Inc. Has $890,000 Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Charles Schwab Investment Management Inc. lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 154,827 shares of the biotechnology company’s stock after selling 7,571 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.73% of Enanta Pharmaceuticals worth $890,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $26,000. FMR LLC boosted its holdings in shares of Enanta Pharmaceuticals by 18.9% in the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 7,839 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. Geode Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 20,478 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Jay R. Luly acquired 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 13.89% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ENTA shares. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, JMP Securities reissued a “market outperform” rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Trading Down 2.6 %

NASDAQ ENTA opened at $5.71 on Monday. The firm has a market capitalization of $121.81 million, a P/E ratio of -1.15 and a beta of 0.48. The firm’s fifty day moving average price is $6.41 and its two-hundred day moving average price is $8.19. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.71 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.